BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Enzychem Lifesciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Enzychem Lifesciences's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06487000-1357@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Mosedipimod: Phase 2 readout est. (NCT06487000)
DESCRIPTION:Mosedipimod\, phase 2\, Atopic Dermatitis.\nStudy: Determine th
 e Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to
  Severe Atopic Dermatitis\nEstimated primary completion: October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/mosedipimod#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06487000
URL:https://assetmemo.bio/drug/mosedipimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04569227-1357@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Mosedipimod: Phase 2 readout est. (NCT04569227)
DESCRIPTION:Mosedipimod\, phase 2.\nStudy: Prevention of COVID-19 Infection
  to Severe Pneumonia or ARDS\nEstimated primary completion: 30 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/mosedipimod#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04569227
URL:https://assetmemo.bio/drug/mosedipimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
